Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  The Lancet

• Publication date

  2010-12-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(10)61424-9PMID 21146205
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Importance of achieving a complete response in multiple myeloma, and the impact of novel agents.

  2010cited by this paper
• A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma.

  2010cited by this paper
• Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

  2010cited by this paper
• Hematopoietic stem cell transplantation for multiple myeloma beyond 2010.

  2010cited by this paper
• Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

  2010cited by this paper
• Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.

  2010cited by this paper
• Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

  2010cited by this paper
• Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

  2009cited by this paper
• Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma.

  2009cited by this paper
• Cyclophosphamide, bortezomib and dexamethasone (CyBorD) induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial

  2009cited by this paper
• How I treat multiple myeloma in younger patients.

  2009cited by this paper
• Bortezomib Plus Dexamethasone (VD)Versus Reduced-dose bortezomib Plus Thalidomide Plus Dexametasone (vTD) as Induction Treatment Prior to Autologous Stem-Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM)

  2009cited by this paper
• Thalidomide / Dexamethasone (TD) Vs. Bortezomib (Velcade)â/Thalidomide / Dexamethasone (VTD) Vs. VBMCP/VBAD/Velcadeâ as Induction Regimens Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): Results of a Phase III PETHEMA/GEM Trial.

  2009cited by this paper
• Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy

  2009cited by this paper
• Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

  2008cited by this paper
• First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)

  2008cited by this paper
• Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.

  2008cited by this paper
• Clinically relevant end points and new drug approvals for myeloma

  2008cited by this paper
• Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.

  2008cited by this paper
• VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma

  2008cited by this paper
• Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma.

  2008cited by this paper
• Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.

  2008cited by this paper
• Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.

  2007cited by this paper
• Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study.

  2007cited by this paper
• Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma

  2007cited by this paper
• Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma

  2007cited by this paper
• International uniform response criteria for multiple myeloma

  2007cited by this paper
• International uniform response criteria for multiple myeloma

  2006cited by this paper
• Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.

  2006cited by this paper
• Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission.

  2006cited by this paper
• Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.

  2006cited by this paper
• Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.

  2005cited by this paper
• International staging system for multiple myeloma.

  2005cited by this paper
• A phase 2 study of bortezomib in relapsed, refractory myeloma.

  2003cited by this paper
• High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

  2003cited by this paper
• CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION

  1998cited by this paper
• A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.

  1996cited by this paper
• A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma

  1996cited by this paper

• Salvage or Second Autologous SCT in Relapsed Multiple Myeloma (2016–2026): A Decade in Review

  2026cites this paper
• The Evolving Landscape of Anti-Clonal Therapy in Newly Diagnosed Systemic Light-Chain (AL) Amyloidosis: Evidence- and Time-Based Comparison with Multiple Myeloma.

  2026cites this paper
• Pretreatment hemoglobin, myeloma subtype, and induction regimens as independent prognostic factors for survival after autologous stem cell transplantation in multiple myeloma: A retrospective cohort study.

  2025cites this paper
• Autologous stem-cell transplantation and maintenance therapy for transplant-eligible multiple myeloma patients: cost-effectiveness analysis based on a network meta-analysis

  2025cites this paper
• Efficacy of maintenance or consolidation therapy for multiple myeloma based on proteasome inhibitors: a meta-analysis

  2025cites this paper
• Frontline management of multiple myeloma patients: optimizing treatment for patients in the Gulf region

  2025cites this paper
• Cost-effectiveness analysis of combination therapies involving novel agents for first/second-relapse patients with multiple myeloma: a Markov model approach with calibration techniques

  2025cites this paper
• 35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience

  2025cites this paper
• Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients

  2025cites this paper
• Evaluation of Clinical Characteristics and Prognostic Factors of Early Progressive Disease (EPD) in Newly Diagnosed Multiple Myeloma Patients: Real-World Data of the Greek Myeloma Study Group.

  2025cites this paper
• Pretreatment hemoglobin, myeloma subtype, and induction regimens as independent prognostic factors for survival after autologous stem cell transplantation in multiple myeloma: a retrospective cohort study

  2025cites this paper
• Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis

  2025cites this paper
• Impact of Genetic Polymorphisms in NF-ĸB2 and TRAF3 Genes on Response to Bortezomib-Based Therapy in Multiple Myeloma Patients

  2024cites this paper
• Autologous HSCT with novel agent‐based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma

  2024cites this paper
• Improved long-term survival rate in the responders to bortezomib, cyclophosphamide, dexamethasone induction therapy in a transplant-eligible cohort of predominantly middle-age multiple myeloma patients

  2024cites this paper
• Impact of second autologous stem‐cell transplantation at relapsed multiple myeloma: A French multicentric real‐life study

  2024cites this paper
• Psychoneuroimmunology in multiple myeloma and autologous hematopoietic stem cell transplant: Opportunities for research among patients and caregivers.

  2024cites this paper
• Induction prior to autologous haematopoietic cell transplantation in multiple myeloma

  2024cites this paper
• Risk factors of early disease progression and decreased survival for multiple myeloma patients after upfront autologous stem cell transplantation

  2024cites this paper
• Enhanced clinical outcomes with radiotherapy in diagnostically challenging intracranial plasmacytomas: Analysis of 190 cases

  2024cites this paper
• Real-World Outcomes in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma Treated With Bortezomib/Cyclophosphamide/Dexamethasone and Bortezomib/Lenalidomide/Dexamethasone as Upfront Treatment

  2024cites this paper
• Feasibility and Outcome of First-Line Autotransplant-Based Treatment in Newly Diagnosed Multiple Myeloma Patients Aged > 65 Years: Monocentric Retrospective Real-World Analysis

  2024cites this paper
• Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma over Three Decades.

  2024cites this paper
• Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation

  2023cites this paper
• Preliminary analysis of explainable machine learning methods for multiple myeloma chemotherapy treatment recognition

  2023cites this paper
• First-line treatment of multiple myeloma in both transplant and non-transplant candidates

  2023cites this paper
• Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma

  2023cites this paper
• Clinical profiles and outcomes of young versus elderly patients with multiple myeloma: A retrospective observational study from a tertiary cancer center in South India

  2023cites this paper
• Response adaptive salvage with KTd and ASCT for functional high‐risk multiple myeloma—The Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial

  2023cites this paper
• Autologous Stem Cell Transplant in Hodgkin’s and Non-Hodgkin’s Lymphoma, Multiple Myeloma, and AL Amyloidosis

  2023influential citation
• The three pillars in treating antibody-mediated encephalitis

  2023cites this paper
• Outcomes of young adults (aged ≤ 40 years) with newly diagnosed multiple myeloma after up‐front autologous stem cell transplant

  2023cites this paper
• Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma

  2023cites this paper
• Assessing Osteolytic Lesion Size on Sequential CT Scans Is a Reliable Study Endpoint for Bone Remineralization in Newly Diagnosed Multiple Myeloma

  2023cites this paper
• Aiming for the cure in myeloma: Putting our best foot forward.

  2023cites this paper
• Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial

  2023cites this paper
• Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting

  2023cites this paper
• Kinase Inhibition in Multiple Myeloma: Current Scenario and Clinical Perspectives

  2022cites this paper
• Response and Survival Estimates of Patients With Plasma Cell Myeloma in a Resource-Constrained Setting Using Protocols From High-Income Countries: A Single-Center Experience From Sri Lanka

  2022cites this paper
• Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study

  2022cites this paper
• Treatment horizon in multiple myeloma

  2022cites this paper
• Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805)

  2022cites this paper
• Multiple myeloma: 2022 update on diagnosis, risk stratification, and management

  2022cites this paper
• Improvement in Post-Autologous Stem Cell Transplant Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience

  2022cites this paper
• Clinical impact of spine magnetic resonance imaging as a valuable prognostic tool for patients with multiple myeloma: a retrospective study

  2022cites this paper
• Drug resistance and minimal residual disease in multiple myeloma

  2022cites this paper
• Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.

  2022cites this paper
• Current approaches to management of newly diagnosed multiple myeloma

  2022influential citation
• Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

  2022cites this paper
• ASTCT Clinical Practice recommendations for transplant and cellular therapies in multiple myeloma.

  2022cites this paper
• Daratumumab: A review of current indications and future directions.

  2022cites this paper
• Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial.

  2022cites this paper
• The MODIFY Study Protocol: An Open-Label, Single-Arm, Multicenter, Prospective Pragmatic Study of Ixazomib-Based Triple-Drug Therapy in Chinese Patients with Multiple Myeloma

  2022cites this paper
• Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?

  2022cites this paper
• Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira – 2022. Part I

  2022cites this paper
• Newly diagnosed multiple myeloma: making sense of the menu.

  2022cites this paper
• Risk Assessment for Newly Diagnosed Fit Young Patients with Multiple Myeloma in the Era of Novel Treatment Modalities: Should There Be Additional Factors Taken into Consideration??

  2022cites this paper
• Triplet RVd Induction for Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis

  2022cites this paper
• Ikaros Proteins in Tumor: Current Perspectives and New Developments

  2021influential citation
• Pretransplant Determinants of Outcome in Patients with Myeloma Undergoing Autologous Transplantation in Lower Resource Settings

  2021cites this paper
• Stratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM

  2021cites this paper
• Weekly as Opposed to Bi-Weekly Bortezomib as Part of Induction Chemotherapy in Newly Diagnosed Multiple Myeloma is Better Tolerated and Equally Efficient in Terms of Initial Therapeutic Response: Real-World Data from a Retrospective Audit

  2021cites this paper
• Genome Instability in Multiple Myeloma: Facts and Factors

  2021cites this paper
• How I Treat High-risk Multiple Myeloma.

  2021cites this paper
• Roadmap to cure multiple myeloma.

  2021cites this paper
• Multiple Myeloma-Related Peripheral Neuropathy

  2021cites this paper
• Clarifying the molecular mechanism of tomentosin-induced antiproliferative and proapoptotic effects in human multiple myeloma via gene expression profile and genetic interaction network analysis

  2021cites this paper
• Investigating the Interplay between Myeloma Cells and Bone Marrow Stromal Cells in the Development of Drug Resistance: Dissecting the Role of Epigenetic Modifications

  2021cites this paper
• Cross fire: Daratumumab-based therapies are standard of care in newly diagnosed multiple myeloma.

  2021cites this paper
• Knowing the unknowns in high risk multiple myeloma.

  2021cites this paper
• Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.

  2021cites this paper
• The Influence of Cell Cycle Regulation on Chemotherapy

  2021cites this paper
• Cyclophosphamide, Thalidomide, and Dexamethasone as Initial Therapy for Patients With Newly Diagnosed Multiple Myeloma in a Middle-Income Country: 7-Year Follow-Up

  2021cites this paper
• Initial Therapeutic Approaches to Patients with Multiple Myeloma

  2021influential citation
• Safety of outpatient stem cell mobilization with low‐ or intermediate‐dose cyclophosphamide in newly diagnosed multiple myeloma patients

  2021cites this paper
• Phase II clinical trial of personalized VCD-VTD sequential therapy using the Vulnerable Elders Survey-13 (VES-13) for transplant-ineligible patients with newly diagnosed multiple myeloma

  2021cites this paper
• Epidemiology, genetics and treatment of multiple myeloma and precursor diseases

  2021cites this paper
• Aberrant Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts, Assessed by Next-Generation Flow Cytometry, Is a Negative Predictor for Deep Response Post Autologous Transplantation in Multiple Myeloma; A Prospective Study in 199 Patients

  2021cites this paper
• The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma

  2021cites this paper
• Role of 1q21 in Multiple Myeloma: From Pathogenesis to Possible Therapeutic Targets

  2021cites this paper
• Immunomodulators in newly diagnosed multiple myeloma: current and future concepts

  2021cites this paper
• Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study

  2021cites this paper
• Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline

  2021cites this paper
• Prognostic impact of early‐versus‐late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMT

  2021cites this paper
• Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?

  2021cites this paper
• Upfront Carfilzomib, Lenalidomide, Dexamethasone with Transplant in Multiple Myeloma Patients, the IFM KRd final results.

  2021cites this paper
• New regimens and directions in the management of newly diagnosed multiple myeloma

  2021influential citation
• Strategies to Overcome High-Risk Multiple Myeloma

  2021cites this paper
• Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications

  2021cites this paper
• A new prediction model integrated serum lipid profile for patients with multiple myeloma

  2021cites this paper
• Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma

  2021cites this paper
• Multiple myeloma – 2020 update on diagnosis and management

  2020cites this paper
• A phase 1b study of once‐weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma

  2020cites this paper
• Efficacy of VRD（Bortezomib, Lenalidomide, and Dexamethasone) Consolidation Therapy and Maintenance Therapy with Immunomodulatory Drugs（Thalidomide or Lenalidomide) after Autologous Peripheral Blood Stem Cell Transplantation in the Era of Bortezomib-Containing Induction Therapy―A Single Institution E

  2020cites this paper
• How I manage frontline transplant-eligible multiple myeloma in Italy

  2020cites this paper
• Multiple Myeloma-Effect of Induction Therapy on Transplant Outcomes.

  2020cites this paper
• Shaping the Treatment Paradigm Based on the Current Understanding of the Pathobiology of Multiple Myeloma: An Overview

  2020cites this paper
• Autologous stem cell transplantation in the treatment of multiple myeloma with 17p deletion

  2020cites this paper
• Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.

  2020cites this paper
• Post-transplant consolidation based on combination of lenalidomide and proteasome inhibitors in multiple myeloma.

  2020cites this paper